We wish to inform you that the company has introduced in-house molecular department for all tests. This is for information and dissemination to the public at large.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Clinitech Laboratory has set up an in-house molecular department to handle all molecular tests under one roof. The move is aimed at serving patient needs more comprehensively without relying on outside labs. The company has not shared any revenue, cost, or capacity details tied to this expansion. This is a general corporate update filed with BSE for public information.
For shareholders, this signals the company is expanding its in-house testing capabilities, which could improve margins over time by bringing outsourced work in-house, but no immediate financial impact has been disclosed.